Isis Torréns

520 total citations
21 papers, 377 citations indexed

About

Isis Torréns is a scholar working on Immunology, Molecular Biology and Epidemiology. According to data from OpenAlex, Isis Torréns has authored 21 papers receiving a total of 377 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Immunology, 11 papers in Molecular Biology and 6 papers in Epidemiology. Recurrent topics in Isis Torréns's work include Immunotherapy and Immune Responses (9 papers), Cervical Cancer and HPV Research (4 papers) and vaccines and immunoinformatics approaches (4 papers). Isis Torréns is often cited by papers focused on Immunotherapy and Immune Responses (9 papers), Cervical Cancer and HPV Research (4 papers) and vaccines and immunoinformatics approaches (4 papers). Isis Torréns collaborates with scholars based in Cuba, South Africa and Austria. Isis Torréns's co-authors include Osvaldo Reyes, Boris Acevedo, Viviana Falcón, Silvio E. Perea, Nelson Santiago Vispo, Ariana García‐Ojalvo, Ricardo Silva, Ernesto López‐Morales, Daniel F. Alonso and José de la Fuente and has published in prestigious journals such as PLoS ONE, Cancer Research and Biochemical and Biophysical Research Communications.

In The Last Decade

Isis Torréns

20 papers receiving 364 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Isis Torréns Cuba 11 225 147 63 45 45 21 377
E Wolff Germany 12 192 0.9× 102 0.7× 40 0.6× 74 1.6× 86 1.9× 17 398
Paul A. Aeed United States 11 302 1.3× 140 1.0× 44 0.7× 80 1.8× 42 0.9× 17 532
Matt Devalaraja United States 5 206 0.9× 141 1.0× 28 0.4× 99 2.2× 45 1.0× 6 393
W Budzyński United States 10 200 0.9× 239 1.6× 44 0.7× 76 1.7× 53 1.2× 24 394
Toshiko Takahashi Japan 12 341 1.5× 180 1.2× 23 0.4× 72 1.6× 38 0.8× 34 549
Irina Mirkina Austria 16 191 0.8× 308 2.1× 47 0.7× 59 1.3× 34 0.8× 26 590
Yuanke Li United States 10 226 1.0× 86 0.6× 35 0.6× 116 2.6× 27 0.6× 19 455
József Antal Hungary 8 137 0.6× 214 1.5× 52 0.8× 23 0.5× 30 0.7× 15 396
Yongyong Ji China 10 202 0.9× 365 2.5× 63 1.0× 54 1.2× 24 0.5× 18 542
F Ghani United States 4 170 0.8× 61 0.4× 35 0.6× 96 2.1× 89 2.0× 8 397

Countries citing papers authored by Isis Torréns

Since Specialization
Citations

This map shows the geographic impact of Isis Torréns's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isis Torréns with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isis Torréns more than expected).

Fields of papers citing papers by Isis Torréns

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Isis Torréns. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isis Torréns. The network helps show where Isis Torréns may publish in the future.

Co-authorship network of co-authors of Isis Torréns

This figure shows the co-authorship network connecting the top 25 collaborators of Isis Torréns. A scholar is included among the top collaborators of Isis Torréns based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Isis Torréns. Isis Torréns is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Limonta‐Fernández, Miladys, et al.. (2018). Biological activity of LALF32-51–E7, a vaccine candidate for the treatment of anogenital lesions associated to HPV16. 4(2). 71–74. 1 indexed citations
3.
Suárez, José Antonio, et al.. (2017). LALF32-51-E7 therapeutic vaccine induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the lungs. Clinical & Experimental Metastasis. 34(3-4). 241–249. 4 indexed citations
4.
Weber, Brandon, et al.. (2017). Expression optimization of a cell membrane-penetrating human papillomavirus type 16 therapeutic vaccine candidate in Nicotiana benthamiana. PLoS ONE. 12(8). e0183177–e0183177. 12 indexed citations
5.
Torréns, Isis, et al.. (2017). LALF32‐51‐E7, a HPV‐16 therapeutic vaccine candidate, forms protein body‐like structures when expressed in Nicotiana benthamiana leaves. Plant Biotechnology Journal. 16(2). 628–637. 11 indexed citations
6.
7.
Musacchio, Alexis, Mónica Béquet‐Romero, Lázaro Betancourt, et al.. (2013). Expression, purification and characterization of a recombinant fusion protein based on the human papillomavirus-16 E7 antigen. SpringerPlus. 2(1). 12–12. 10 indexed citations
8.
9.
Guillén, Gerardo, Julio Aguilar, Lisset Hermida, et al.. (2010). Virus-Like Particles as vaccine antigens and adjuvants: application to chronic disease, cancer immunotherapy and infectious disease preventive strategies. 2(2). 128–133. 16 indexed citations
10.
Vallespí, Maribel Guerra, Julio R. Fernández, Isis Torréns, et al.. (2009). Identification of a novel antitumor peptide based on the screening of an Ala‐library derived from the LALF32–51 region. Journal of Peptide Science. 16(1). 40–47. 18 indexed citations
11.
Torréns, Isis, et al.. (2008). Human papillomavirus vaccines: current status and perspectives. Biotecnología aplicada. 25(1). 1–6. 2 indexed citations
12.
Béquet‐Romero, Mónica, Marta Ayala, Boris Acevedo, et al.. (2007). Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice. Angiogenesis. 10(1). 23–34. 19 indexed citations
13.
Torréns, Isis, et al.. (2005). Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors. Vaccine. 23(50). 5768–5774. 30 indexed citations
14.
Reyes, Osvaldo, et al.. (2004). Profiling the immune responses of human patients treated with recombinant streptokinase after myocardial infarct. Molecular Diversity. 8(3). 251–256. 1 indexed citations
15.
Perea, Silvio E., Osvaldo Reyes, Nelson Santiago Vispo, et al.. (2004). Antitumor Effect of a Novel Proapoptotic Peptide that Impairs the Phosphorylation by the Protein Kinase 2 (Casein Kinase 2). Cancer Research. 64(19). 7127–7129. 117 indexed citations
16.
Torréns, Isis, et al.. (2000). A mutant streptokinase lacking the C-terminal 42 amino acids is less immunogenic. Immunology Letters. 70(3). 213–218. 21 indexed citations
17.
García‐Ojalvo, Ariana, et al.. (1999). Prevalence of Circulating Antibodies against a Streptokinase C-Terminal Peptide in Normal Blood Donors. Biochemical and Biophysical Research Communications. 263(2). 454–459. 6 indexed citations
18.
Torréns, Isis, Osvaldo Reyes, Ariana García‐Ojalvo, et al.. (1999). Mapping of the Antigenic Regions of Streptokinase in Humans after Streptokinase Therapy. Biochemical and Biophysical Research Communications. 259(1). 162–168. 20 indexed citations
19.
Torréns, Isis, et al.. (1999). A Mutant Streptokinase Lacking the C-Terminal 42 Amino Acids Is Less Reactive with Preexisting Antibodies in Patient Sera. Biochemical and Biophysical Research Communications. 266(1). 230–236. 8 indexed citations
20.
Pupo, Elder, et al.. (1999). Two streptokinase genes are expressed with different solubility in Escherichia coli W3110. Biotechnology Letters. 21(12). 1119–1123. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by E Wolff Breakdown of academic impact, for papers by Paul A. Aeed Breakdown of academic impact, for papers by Matt Devalaraja Breakdown of academic impact, for papers by W Budzyński Breakdown of academic impact, for papers by Toshiko Takahashi Breakdown of academic impact, for papers by Irina Mirkina Breakdown of academic impact, for papers by Yuanke Li Breakdown of academic impact, for papers by József Antal Breakdown of academic impact, for papers by Yongyong Ji Breakdown of academic impact, for papers by F Ghani
Rankless by CCL
2026